Abstract:e19008 Background: Stage IV non-small cell lung cancer (NSCLC) carries a poor prognosis with a median survivals of 8-10 months. The standard treatment has traditionally been systemic chemotherapy and palliative radiotherapy for symptom relief. Some data has suggested that patients with oligometastatic NSCLC may benefit from aggressive thoracic radiotherapy. The aim of this study was to evaluate the efficacy and toxicity of definitive thoracic concurrent chemoradiation followed by consolidation chemotherapy in oligometastatic NSCLC. Methods: Patients with oligometastatic NSCLC, aged ≤ 75 years, and WHO performance status of 0-1 were enrolled. Oligometastatic NSCLC was defined as 5 or fewer distant metastatic lesions at diagnosis. Patients were treated with definitive thoracic radiotherapy (biological equivalent dose ≥ 60Gy) concurrent with platinum-based, two-drug chemotherapy. After concurrent chemoradiation, patients received 2-4 cycles of consolidation chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary end points were objective remission rate (ORR), overall survival (OS) and toxicity. Results: Between Jane 2008 and Jane 2013, 64 patients were enrolled. Median age was 62 years (range: 41-70 years). Median prescribed radiation dose to primary tumor was 72Gy. The median number of chemotherapy cycles was 4 (range 2-6). The confirmed ORR was 70.3% (10.9% CR and 59.4% PR). At a median follow-up of 28 months, the median PFS and OS were 14 months and 26 months, respectively. The 1-, 2-, and 3-year PFS were 56.3%, 25.6%, 7.4%, respectively. The 1-, 2-, 3-, 4-, and 5-year OS were 71.9%, 52.5%, 31.4%, 25.1% and 14.8%, respectively. Toxicities were generally mild, including grade 2/3 radiation pneumonitis (10.9%), grade 2/3 radiation esophagitis (17.2%), grade 3/4 neutropenia (39.1%), grade 3/4 thrombocytopenia (15.6%), and grade 3/4 anemia (10.9%). Conclusions: Thoracic concurrent chemoradiation followed by consolidation chemotherapy showed a promising efficacy and an acceptable tolerability profile for patients with oligometastatic NSCLC. Further larger and randomized controlled trials are warranted.

Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.

Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis

Safety and Efficacy of Thoracic Radiotherapy Combined with Chemo-Immunotherapy in Patients with Extensive-Stage Small Cell Lung Cancer: a Multicenter Retrospective Analysis.

Timing of Thoracic Radiotherapy in the Treatment of Extensive-Stage Small-Cell Lung Cancer: Important or Not?

Role of consolidative thoracic radiation in extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: a retrospective study from a single cancer center

Consolidative thoracic radiation could not improve survival of extensive-stage small-cell lung cancer with first-line chemoimmunotherapy: results from a single cancer center

Thorax radiotherapy using 18F-positron emission tomography/computed tomography-guided precision radiotherapy is a prognostic factor for survival in patients with extracranial oligometastatic non-small cell lung cancer:A two-center propensity score-matched analysis

Radiotherapy for Oligometastatic Tumor Improved the Prognosis of Patients with Non‐small Cell Lung Cancer (NSCLC)

Receipt of Thoracic Radiation Therapy and Radiotherapy Dose Are Correlated with Outcomes in a Retrospective Study of Three Hundred and Six Patients with Extensive Stage Small-Cell Lung Cancer.

Thoracic Radiotherapy Improves the Survival in Patients With EGFR-Mutated Oligo-Organ Metastatic Non–Small Cell Lung Cancer Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors: A Multicenter, Randomized, Controlled, Phase III Trial

Real-world Outcomes of PD-L1 Inhibitors Combined with Thoracic Radiotherapy in the First-Line Treatment of Extensive Stage Small Cell Lung Cancer.

Radiotherapy Improves the Survival of Patients with Extensive-Disease Small-Cell Lung Cancer: a Propensity Score Matched Analysis of Surveillance, Epidemiology, and End Results Database.

Risk Prediction Model for Synchronous Oligometastatic Non-Small Cell Lung Cancer: Thoracic Radiotherapy May Not Prolong Survival in High-Risk patients

Thoracic radiation therapy could give survival benefit to elderly patients with extensive-stage small-cell lung cancer.

Effects of Thoracic Radiotherapy Timing and Duration on Progression‐free Survival in Limited‐stage Small Cell Lung Cancer

First-line Atezolizumab/durvalumab Plus Platinum–etoposide Combined with Radiotherapy in Extensive-Stage Small-Cell Lung Cancer

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non-small cell lung cancer.

A Phase II Prospective Study of Definitive Thoracic Concurrent Chemoradiation Followed by Consolidation Chemotherapy for Oligometastatic Non-Small Cell Lung Cancer.

Increased Biological Effective Dose of Radiation Correlates with Prolonged Survival of Patients with Limited-Stage Small Cell Lung Cancer: A Systematic Review.

Survival benefit of thoracic radiotherapy plus EGFR-TKIs in patients with non-oligometastatic advanced non-small-cell lung cancer: a single-center retrospective study

Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients with Limited-Stage Small-Cell Lung Cancer.